Evidence map›Paper›PMID 30146577›Full record

ArticleInternal medicine (Tokyo, Japan)2019

The Progression of Esophageal Mucosa-associated Lymphoid Tissue Lymphoma after Helicobacter pylori Eradication Therapy: A Case Report and Discussion of Therapeutic Options.

Yukari Takeuchi, Koji Miyahara, Toshiaki Morito, Yoshiko Okikawa, Hideaki Kinugasa, Yuki Moritou, Reiji Higashi, Masaki Kunihiro, Masahiro Nakagawa

Open access · diamondAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine (Tokyo, Japan), 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact, top 88% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Primary Esophageal Mucosa-associated Lymphoid Tissue Lymphoma: A Rare Case Report and Review of Other Published Data.The Korean journal of helicobacter and upper gastrointestinal research · 2023
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 1 institution in 1 country.

Yukari TakeuchiDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Koji MiyaharaDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Toshiaki MoritoDepartment of Pathology, Hiroshima City Hospital, Japan.
Yoshiko OkikawaDepartment of Hematology, Hiroshima City Hospital, Japan.
Hideaki KinugasaDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Yuki MoritouDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Reiji HigashiDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Masaki KunihiroDepartment of Internal Medicine, Hiroshima City Hospital, Japan.
Masahiro NakagawaDepartment of Endoscopy, Hiroshima City Hospital, Japan.
Hiroshima Prefectural Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

A 50-year-old woman with epigastric discomfort was referred to our hospital. Esophagogastroduodenoscopy showed flat, elevated, submucosal tumor-like lesions in the esophagus. Extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue (MALT lymphoma) of the esophagus was diagnosed based on the examination of an endoscopic biopsy specimen. Computed tomography showed the enlargement of a lymph node in the gastric cardia. The present case showed disease progression despite Helicobacter pylori eradication therapy and achieved partial remission after rituximab monotherapy. The patient remained in partial remission for 20 months. This case suggests that esophageal MALT lymphoma with lymph node involvement does not respond to H. pylori eradication therapy and that it requires systemic treatment.

Indexed as

Helicobacter pyloriAdultAgedAnti-Bacterial AgentsAntineoplastic Agents, ImmunologicalDisease ProgressionEsophageal NeoplasmsFemaleHelicobacter InfectionsHumansLymphoma, B-Cell, Marginal ZoneMaleMiddle AgedRituximabTomography, X-Ray ComputedAnti-Bacterial AgentsAntineoplastic Agents, ImmunologicalRituximaberadication therapyesophagusHelicobacter pyloriMALTrituximab

Identifiers

PMID30146577
PMCPMC6378146
OpenAlexW2888153210

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.